STORM Therapeutics expands R&D leadership team

  • Matthew Fife joins as Senior Vice President of Therapeutics
  • Bet Thomas promoted to Vice President of Pharmaceutical Chemistry

CAMBRIDGE, England, January 10, 2023 /PRNewswire/ — STORM Therapeutics Ltd. (STORM), the clinical-stage biotechnology company discovering and developing new small-molecule therapies targeting RNA-modifying enzymes (RMEs) for oncology and other diseases, today announces the appointment of Matthew Fife as Senior Vice President of Therapeutics and promotion of Bet Thomas to the Vice President of Pharmaceutical Chemistry.

Matthew Fife has over 20 years of experience in drug discovery and development, having previously held senior leadership positions at Sitryx (Oxford), TopiVert (London), horizon (Barcelona) and Prosidion (Oxford). Matthew has successfully conducted multiple research programs in several therapeutic areas, providing clinical candidates who have achieved Phase 2 or beyond in oncology, immunology, metabolic diseases, neurology and ophthalmology. Matthew holds degrees from the University of Glasgow (Three-year degree), Columbia University (MA) and the University of Birmingham (PhD) prior to postdoctoral studies at UCLA with Nobel laureate Sir Fraser Stoddart. He is a licensed chemist, Fellow of the Royal Society of Chemistry, author of over 40 peer-reviewed publications and inventor of over 90 patent applications. Matthew will work with the leadership team to advance the STORM pipeline while working with functional and project leaders to define pharmaceutical chemistry, drug discovery, DMPK, PK-PD, CMC, and preclinical development strategies.

Vice President of newly promoted Pharmaceutical Chemistry, Bet Thomas has over 20 years of medicinal and computational chemistry experience and joined STORM Therapeutics in 2016. In her new role, she will be responsible for medicinal chemistry strategy to enable the discovery and progression of clinical candidates from the portfolio of Storm. Beth has experience in industrial, academic, and nonprofit roles, leading interdisciplinary drug discovery teams at Celltech, UCB, BioFocus, University of Cambridge and the Cambridge Crystallographic Data Centre. Beth has a degree in chemistry from the University of Sant’Andrea and a PhD in polyketide biosynthesis with Professors Staunton and Leadlay at the University of Cambridge.

Oliver RauschChief Scientific Officer of STORM Therapeutics, said: “I am delighted to welcome Matthew to the STORM leadership team. His extensive experience and insight will be invaluable as the team continues to develop its strategies and advance our innovative pipeline of discoveries to benefit cancer patients. of Beth is a credit to her talent, dedication and continued commitment to STORM as she steps forward to take the overall lead in pharmaceutical chemistry efforts across our pipeline of discoveries.”

Matthew FifeSenior Vice President of STORM Therapeutics, commented: “I am thrilled to be joining this strong and experienced drug discovery and development team. I look forward to using my experience and knowledge for the advancement of STORM’s innovative drug candidates, which have the potential to transform and ultimately improve patient outcomes.”

Bet ThomasVice President of Pharmaceutical Chemistry at STORM Therapeutics, added: “I am passionate about the pioneering work we are undertaking at STORM in leading projects on new drug targets to create new therapies and I am excited to take on this new role as Vice President of Medicinal Chemistry.”

The appointment and promotion follows STORM’s recent USD close $30 million Series B funding and the initiation of a Phase 1 clinical trial of its first candidate STC-15, a highly selective, orally bioavailable METTL3 inhibitor, which has initiated a clinical trial in cancer patients with solid tumors in November 2022. Study details can be found at clinicaltrials.gov under the identifier NCT05584111. The first results of the Phase 1 study are expected to be presented in 2023.

About STORM Therapeutics

STORM Therapeutics (STORM) is a clinical-stage biotechnology company creating novel therapies that inhibit RNA-modifying enzymes (RMEs) for use in oncology and other diseases. More than 150 RNA modifications and approximately 300 RNA-modifying enzymes have been reported and represent novel therapeutic targets.

STORM leveraged its first-mover advantage to establish a novel drug discovery and RNA analysis platform leading to the identification of novel targets and a proprietary pipeline of best-in-class small molecule drug candidates for potential use in oncology , inflammation, viral infection and CNS diseases.

The pipeline is exemplified by STORM’s METTL3 inhibitor, STC-15, which received IND approval and began its Phase 1 clinical trial in cancer patients in November 2022. STC-15 represents the first RNA-modifying enzyme inhibitor to enter clinical evaluation in humans. Further plans are planned for advancement in IND-track activities in 2023.

Fierce Biotech named STORM as one of its “Fierce 15” of 2022, designating it as one of the most innovative and exciting biotech companies in the industry, pioneering new drug targets.

STORM’s investors include M Ventures, Pfizer Ventures, Taiho Ventures LLC, Cambridge Innovation Capital I Limited, Seroba Life Sciences, IP Group plc, Fast Track Initiative (FTI) and UTokyo Innovation Platform Co., Ltd. (UTokyo IPC).

For more information, visit www.stormtherapeutics.com

About STC-15

STORM’s Leading Clinical Program STC-15 is a first-in-class inhibitor of RNA modification and is the first RNA methyltransferase inhibitor to enter clinical development. STC-15 is an oral small molecule that inhibits METTL3, an RNA methyltransferase implicated in oncology and other diseases. Some RNA methyltransferases are important regulators of RNA sensing and innate immune activation and represent novel immunoregulatory targets.

STC-15 has also been shown to inhibit tumor growth through mechanisms involving antitumor immune responses, such as changes in interferon signaling and synergy with T-cell checkpoint blockade. Additionally, this compound has demonstrated efficacy in models of leukemia through mechanisms such as inhibition of leukemia stem cell function.

STORM has begun dosing of the first patient in a Phase 1 clinical study of STC-15 in patients living with solid tumors in November 2022 and plans to present the results of its study in 2023.

STORM SOURCE Therapeutic

Add a Comment

Your email address will not be published. Required fields are marked *